Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT02564900 (Clinical Trials/ DS-8201a)

Study Title
Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors (NCT02564900)

Trial Description
This is an open-label, two-part, multiple study to evaluate the safety and tolerability of DS-8201a in patients with advanced solid malignant tumors.

This trial is sponsored by Daiichi Sankyo Co., Ltd

Study Data

  • Condition: Advanced Solid Tumors
  • Interventions:
    • Drugs used in this trial
      • DS-8201a
  • Phase: I
  • Enrollment: 198
  • Start: August 2015
  • Estimated Completion: March 2018
  • Last verified:  April 2017
  • Last updated: April 2017

Study Schematic

NCT02564900

Click here to Return to Drug map


Last Editorial review: August 30, 2017
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015-2017 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar